Aspectos actuales sobre el cribado en el cáncer de próstata

  1. A. Jalón Monzón 1
  2. S. Escaf Barmadah 1
  3. L.M. Viña Alonso 2
  4. M. Jalón Monzón 3
  1. 1 Hospital Universitario Central de Asturias (HUCA), Oviedo, Asturias, España
  2. 2 Centro de Salud El Parque-Somió, Gijón, Asturias, España
  3. 3 Centro de Salud de Contrueces, Gijón, Asturias, España
Mostrar afiliaciones +
Revista:
Semergen: revista española de medicina de familia

ISSN: 1138-3593

Año de publicación: 2017

Número: 5

Páginas: 387-393

Tipo: Artículo

DOI: 10.1016/J.SEMERG.2016.07.002 DIALNET GOOGLE SCHOLAR

Otras publicaciones en: Semergen: revista española de medicina de familia

Objetivos de desarrollo sostenible

Resumen

Los programas de cribado de cáncer de próstata basados en la determinación sérica del antígeno específico de próstata han llevado a un sobrediagnóstico y, como consecuencia, a un sobretratamiento. Un porcentaje de varones diagnosticados de cáncer de próstata tienen un tumor que no progresará o lo hará lentamente (sobrediagnóstico o pseudoenfermedad). Esta tasa de sobrediagnóstico oscila entre el 17-50%. El cribado poblacional se define como la exploración sistemática de hombres asintomáticos. La detección precoz o cribado oportunista conlleva la búsqueda de casos individuales, siendo iniciada por el médico o el propio paciente. Ante un paciente que acuda a consulta solicitando un antígeno específico de próstata se le deben explicar una serie de cuestiones relativas al sobrediagnóstico, el sobretratamiento y los posibles daños derivados de la biopsia. Con los datos de los estudios aleatorizados sobre el antígeno específico de próstata y el cribado de cáncer de próstata, ninguna sociedad urológica recomienda realizar cribado poblacional.

Referencias bibliográficas

  • J. Ferlay, D.M. Parkin, E. Steliarova-Foucher Estimates of cancer incidence and mortality in Europe in 2008 Eur J Cancer, 46 (2010), pp. 765-781 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • R.L. Siegel, K.D. Miller, A. Jemal Cancer statistics, 2015 CA Cancer J Clin., 65 (2015), pp. 5-29 View PDFCrossRefGoogle Scholar
  • M. Arnold, H.E. Karim-Kos, J.W. Coebergh, G. Byrnes, A. Antilla, J. Ferlay, et al. Recent trends in incidence of five common cancers in 26 European countries since 1988: Analysis of the European Cancer Observatory Eur J Cancer., 51 (2015), pp. 1164-1187 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • R. De Angelis, M. Sant, M.P. Coleman, S. Francisci, P. Baili, D. Pierannunzio, et al., EUROCARE-5 Working Group Cancer survival in Europe 1999-2007 by country and age: Results of EUROCARE-5--A population-based study Lancet Oncol, 15 (2014), pp. 23-34 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • N. Howlader, A.M. Noone, M. Krapcho, N. Neyman, R. Aminou, W. Waldron, et al. SEER cancer statistics review, 1975-2008 National Cancer Institute, Bethesda, MD (2011) Google Scholar
  • J.M. Cozar, B. Miñana, F. Gómez-Veiga, A. Rodríguez-Antolín, H. Villavicencio, A. Cantalapiedra, et al. Registro nacional de cáncer de próstata 2010 en España Actas Urol Esp., 37 (2013), pp. 12-19 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • F.J. Brenes Actividades preventivas en el hombre. Cáncer de próstata D. Ramírez, N. Fernández de Cano, A. de Santiago (Eds.), Actividades preventivas en la consulta de Atención Primaria. SEMERGEN módulo 1., IMC, Madrid (2009), pp. 196-204 View Record in ScopusGoogle Scholar
  • J.H. Hayes, M.J. Barry Screening for prostate cancer with de prostate-specific antigen test. A review of current evidence JAMA., 311 (2014), pp. 1143-1149 View PDFCrossRefView Record in ScopusGoogle Scholar
  • R. Luengo-Fernandez, J. Leal, A. Gray Economic burden of cancer across the European Union: A population-based cost analysis Lancet Oncol, 14 (2013), pp. 1165-1174 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • T.A. Stamey, N. Yang, A.R. Hay, J.E. McNeal, F.S. Freiha, E. Redwine Prostate specific antigen as a serum marker for adenocarcinoma of the prostate N Engl J Med, 317 (1987), pp. 909-916 View Record in ScopusGoogle Scholar
  • J.P. Richie, W.J. Catalona, F.R. Ahmann, M.A. Hudson, P.T. Scardino, R.C. Flanigan, et al. Effect of patient age on early detection of prostate cancer with serum prostate-specific antigen and digital rectal examination Urology, 42 (1993), pp. 365-374 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • C. Gosselaar, M.J. Roobol, S. Roemeling, F.H. Schröder The role of the digital rectal examination in subsequent screening visits in the European randomized study of screening for prostate cancer (ERSPC), Rotterdam Eur Urol, 54 (2008), pp. 581-588 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • M.K. Brawer, R. Kirby Antígeno específico prostático. Fast Facts J & C Ediciones médicas, Barcelona (2001) Google Scholar
  • W.J. Catalona, J.P. Richie, F.R. Ahmann, M.A. Hudson, P.T. Scardino, R.C. Flanigan Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: Results of a multicenter clinical trial of 6,630 men J Urol, 151 (1994), pp. 1283-1290 ArticleDownload PDFCrossRefView Record in ScopusGoogle Scholar
  • Mottet N, Bellmunt J, Briers E, van den Bergh RC, Bolla M, van Casteren NJ, et al. Guidelines on prostate cancer. Europen Association of Urology (EAU); 2015. Disponible en: http://uroweb.org/wp-content/uploads/EAU-Guidelines-Prostate-Cancer-2015-v2.pdf Google Scholar
  • R. Etzioni, R. Gulati, M.R. Cooperberg, D.M. Penson, N.S. Weiss, I.M. Thompson Limitations of basing screening policies on screening trials: The US Preventive Services Task Force and Prostate Cancer Screening Med Care, 51 (2013), pp. 295-300 View Record in ScopusGoogle Scholar
  • Ilic D, Neuberger MM, Djulbegovic M, Dahm P. Screening for prostate cáncer. Cochrane Database Syst Rev. 2013;(1):CD004720. Google Scholar
  • M.J. Barry PSA screening for prostate cancer: The current controversy--A viewpoint. Patient outcomes research team for prostatic diseases Ann Oncol, 9 (1998), pp. 1279-1282 ArticleDownload PDFCrossRefView Record in ScopusGoogle Scholar
  • V.A. Moyer Screening for prostate cancer: US Preventive Service Task Force Recommendation statement Ann Intern Med., 157 (2012), pp. 120-135 View PDFCrossRefGoogle Scholar
  • A.B. Miller New data on prostate-cancer mortality after PSA screening N Engl J Med., 366 (2012), pp. 1047-1048 View PDFCrossRefView Record in ScopusGoogle Scholar
  • I.M. Thompson, P.J. Goodman, C.M. Tangen, M.S. Lucia, G.J. Miller, L.G. Ford, et al. The influence of finasteride on the development of prostate cancer N Engl J Med., 349 (2003), pp. 215-224 View Record in ScopusGoogle Scholar
  • H.B. Carter, M.E. Allaf, A.W. Partin Diagnóstico y estadificación del cáncer de próstata A.J. Wein, L.R. Kavoussi, A.C. Novick, A.W. Partin, C.A. Peters (Eds.), Campbell-Walsh Urología (9.a ed.), Médica Panamericana (2008), pp. 2912-2931 Google Scholar
  • H. Vasarainen, H. Malmi, L. Määttänen, M. Ruutu, T. Tammela, K. Taari, et al. Effects of prostate cancer screening on health-related quality of life: Results of the Finnish arm of the European randomized screening trial (ERSPC) Acta Oncol, 52 (2013), pp. 1615-1621 View PDFCrossRefView Record in ScopusGoogle Scholar
  • E.A. Heijnsdijk, E.M. Wever, A. Auvinen, J. Hugosson, S. Ciatto, V. Nelen, et al. Quality-of-life effects of prostate-specific antigen screening N Engl J Med, 367 (2012), pp. 595-605 View PDFCrossRefView Record in ScopusGoogle Scholar
  • Mohler JL, Armstrong AJ, Bahnson RR, Boston B, Busby JE, D’Amico AV, et al. NCCN Clinical Practice Guidelines in Oncology TM: Prostate cancer early detection, V.2. 2012, p. 15. Disponible en: https://www.nccn.org/patients/guidelines/prostate/index.html#4 Google Scholar
  • S.M. Alibhai, M. Leach, G. Tomlinson, M.D. Krahn, N. Fleshner, E. Holowaty, et al. 30-day mortality and major complications after radical prostatectomy: Influence of age and comorbidity J Natl Cancer Inst, 97 (2005), pp. 1525-1532 View PDFCrossRefView Record in ScopusGoogle Scholar
  • M-A. Kalogeridi, G. Kyrgias, A. Zygogianni, J. Kouvaris, K. Theodorou, N. Kelekis, et al. Challenges and choices in prostate cancer irradiation: From the three dimensional conformal radiotherapy to the era of intensity modulated, image-guided and adaptive radiation treatment Urol J, 11 (2014), pp. 1925-1931 View Record in ScopusGoogle Scholar
  • G.L. Andriole, E.D. Crawford, R.L. Grubb 3rd, S.S. Buys, D. Chia, T.R. Church, et al. Prostate cancer screening in the randomized prostate, lung, colorectal and ovarian cancer screening trial: Mortality results after 13 years of follow-up J Natl Cancer Inst., 104 (2012), pp. 125-132 View PDFCrossRefView Record in ScopusGoogle Scholar
  • P.F. Pinsky, A. Blacka, B.S. Kramer, A. Miller, P.C. Prorok, C. Berg Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial Clin Trials, 7 (2010), pp. 303-311 View PDFCrossRefView Record in ScopusGoogle Scholar
  • J.E. Shoag, S. Mittal, J.C. Hu Reevaluating PSA testing rates in the PLCO Trial N Engl J Med., 374 (2016), pp. 1795-1796 View PDFCrossRefView Record in ScopusGoogle Scholar
  • F.H. Schröder, J. Hugosson, M.J. Roobol, T.L. Tammela, S. Ciatto, V. Nelen, et al. Screening and prostate-cancer mortality in a randomized European study N Engl J Med., 360 (2009), pp. 1320-1328 View Record in ScopusGoogle Scholar
  • F.H. Schröder, J. Hugosson, M.J. Roobol, T.L. Tammela, S. Ciatto, V. Nelen, et al., ERSPC Investigators Prostate-cancer mortality at 11 years of follow-up N Engl J Med., 366 (2012), pp. 981-990 View Record in ScopusGoogle Scholar
  • F.H. Schröder, J. Hugosson, M.J. Roobol, T.L. Tammela, M. Zappa, V. Nelen, et al. Screening and prostate cancer mortality: Results of the European Randomized Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up Lancet, 384 (2014), pp. 2027-2035 ArticleDownload PDFGoogle Scholar
  • M. Luján, Á. Páez, J.C. Angulo, R. Granados, M. Nevado, G.M. Torres, et al. Contaminación de antígeno específico-prostático a largo plazo en la rama española del Estudio Aleatorizado Europeo de Screening del Cáncer de Próstata (ERSPC) Actas Urol Esp, 40 (2016), pp. 164-172 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • F. Kamangar, G.M. Dores, W.F. Anderson Patterns of cancer incidence, mortality, and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world J Clin Oncol, 24 (2006), pp. 2137-2150 View Record in ScopusGoogle Scholar
  • A.J. Vickers, D. Ulmert, D.D. Sjoberg, C.J. Bennette, T. Björk, A. Gerdtsson, et al. Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: Case-control study BMJ, 346 (2013), p. f2023 View PDFCrossRefView Record in ScopusGoogle Scholar
  • S. Carlsson, M. Assel, D. Sjoberg, D. Ulmert, J. Hugosson, H. Lilja, et al. Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: Population based cohort study BMJ, 348 (2014), p. g2296 View PDFCrossRefView Record in ScopusGoogle Scholar
  • T.J. Wilt, M.K. Brawer, K.M. Jones, M.J. Barry, W.J. Aronson, S. Fox, et al. Radical prostatectomy versus observation for localized prostate cancer N Engl J Med, 367 (2012), pp. 203-213 View PDFCrossRefView Record in ScopusGoogle Scholar
  • G. Bartsch, W. Horninger, H. Klocker, A. Reissigl, W. Oberaigner, D. Schönitzer, et al., Tyrol Prostate Cancer Screening Group Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria Urology, 58 (2001), pp. 417-424 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • J. Hugosson, S. Carlsson, G. Aus, S. Bergdahl, A. Khatami, P. Lodding, et al. Mortality results from the Göteborg randomised population-based prostate-cancer screening trial Lancet Oncol, 11 (2010), pp. 725-732 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • M. Djulbegovic, R.J. Beyth, M.M. Neuberger, T.L. Stoffs, J. Vieweg, B. Djulbegovic, et al. Screeening for prostate cancer: Systematic review and meta-analysis of randomised controlled trials BMJ, 341 (2010), p. c4543 View PDFCrossRefGoogle Scholar
  • J.H. Hayes, M.J. Barry Screening for prostate cancer with the prostate-specific antigen test: A review of current evidence JAMA, 311 (2014), pp. 1143-1149 View PDFCrossRefView Record in ScopusGoogle Scholar
  • C.P. Cooper, T.L. Merrit, L.E. Ross, L.V. John, C.M. Jorgensen To screen or not to screen, when clinical guidelines disagree: Primary care physicians’ use of the PSA test Prev Med., 38 (2004), pp. 182-191 View PDFView Record in ScopusGoogle Scholar
  • R. Meneu La perspectiva de los pacientes GCS, 4 (2002), pp. 3-4 View Record in ScopusGoogle Scholar
Fuente de los datos: Dialnet